Business Description
RUA Life Sciences PLC
ISIN : GB0033360586
Total Employee Number:
40Description
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.63 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 93 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.77 | |||||
Beneish M-Score | -1.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.9 | |||||
3-Year EBITDA Growth Rate | 13.7 | |||||
3-Year EPS without NRI Growth Rate | 19.4 | |||||
3-Year FCF Growth Rate | 29.1 | |||||
3-Year Book Growth Rate | -32.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.13 | |||||
9-Day RSI | 54.25 | |||||
14-Day RSI | 55.48 | |||||
3-1 Month Momentum % | 5.85 | |||||
6-1 Month Momentum % | 30.22 | |||||
12-1 Month Momentum % | 90.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.92 | |||||
Quick Ratio | 4.81 | |||||
Cash Ratio | 2.75 | |||||
Days Inventory | 454 | |||||
Days Sales Outstanding | 98.46 | |||||
Days Payable | 76.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -40.9 | |||||
Shareholder Yield % | 3.03 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.92 | |||||
Operating Margin % | -8.81 | |||||
Net Margin % | -7.32 | |||||
EBITDA Margin % | 0.26 | |||||
FCF Margin % | -29.07 | |||||
OCF Margin % | -27.59 | |||||
ROE % | -2.81 | |||||
ROA % | -2.25 | |||||
ROIC % | -4.31 | |||||
3-Year ROIIC % | 3.13 | |||||
ROC (Joel Greenblatt) % | -6.06 | |||||
ROCE % | -3.05 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 12.13 | |||||
PS Ratio | 5.45 | |||||
PB Ratio | 2.12 | |||||
Price-to-Tangible-Book | 2.42 | |||||
EV-to-EBIT | -54.62 | |||||
EV-to-Forward-EBIT | 12.12 | |||||
EV-to-EBITDA | 1888.43 | |||||
EV-to-Forward-EBITDA | 37.59 | |||||
EV-to-Revenue | 4.81 | |||||
EV-to-Forward-Revenue | 0.95 | |||||
EV-to-FCF | -16.54 | |||||
Price-to-GF-Value | 1.73 | |||||
Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Net-Current-Asset-Value | 4.03 | |||||
| Price-to-Net-Cash | 24.2 | |||||
Earnings Yield (Greenblatt) % | -1.83 | |||||
FCF Yield % | -5.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RUA Life Sciences PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.168 | ||
| EPS (TTM) (€) | -0.004 | ||
| Beta | 1.808 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.07 | ||
| Volatility % | 108.07 | ||
| 14-Day RSI | 55.48 | ||
| 14-Day ATR (€) | 0.014356 | ||
| 20-Day SMA (€) | 0.2231 | ||
| 12-1 Month Momentum % | 90.53 | ||
| 52-Week Range (€) | 0.0815 - 0.348 | ||
| Shares Outstanding (Mil) | 62.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RUA Life Sciences PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RUA Life Sciences PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-06-30 | 0.17 (+0.00%) | ||
| General meeting for 2025 | 2026-03-17 11:00 | 0.11 (+0.00%) | ||
| Annual report for 2025 | 2026-02-12 | 0.12 (+7.83%) | ||
| Fourth quarter earnings results for 2025 | 2026-01-30 | 0.14 (+2.16%) | ||
| Second quarter earnings results for 2025 | 2024-12-11 | 0.10 (-14.47%) | ||
| General meeting for 2024 | 2024-08-27 11:00 | 0.11 (+0.00%) | ||
| Annual report for 2024 | 2024-07-26 | 0.08 (-18.75%) |
Show
Entries
RUA Life Sciences PLC Frequently Asked Questions
What is RUA Life Sciences PLC(FRA:AOHA)'s stock price today?
The current price of FRA:AOHA is €0.24. The 52 week high of FRA:AOHA is €0.35 and 52 week low is €0.08.
When is next earnings date of RUA Life Sciences PLC(FRA:AOHA)?
The next earnings date of RUA Life Sciences PLC(FRA:AOHA) is 2027-01-29 Est..
Does RUA Life Sciences PLC(FRA:AOHA) pay dividends? If so, how much?
RUA Life Sciences PLC(FRA:AOHA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on RUA Life Sciences PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers